ASPRV1

Summary

ASPRV1 (aspartic peptidase retroviral like 1, HGNC:26321) is a protein-coding gene on chromosome 2p13.3, encoding Retroviral-like aspartic protease 1 (Q53RT3). Protease responsible for filaggrin processing, essential for the maintenance of a proper epidermis organization.

Filaggrin is a structural protein that is crucial for in the development and maintenance of the skin barrier. This gene encodes a retroviral-like protease involved in profilaggrin-to-filaggrin processing. Expression is found primarily in the epidermis and inner root sheath of hair follicles.

Source: NCBI Gene 151516 — RefSeq curated summary.

At a glance

• Gene–disease (curated): ichthyosis, lamellar, autosomal dominant (Strong, GenCC)
• GWAS associations: 1
• Clinical variants (ClinVar): 87 total — 3 pathogenic
• Phenotypes (HPO): 23
• MANE Select transcript: NM_152792

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26321
Approved symbol	ASPRV1
Name	aspartic peptidase retroviral like 1
Location	2p13.3
Locus type	gene with protein product
Status	Approved
Aliases	Taps, SASPase, FLJ25084
Ensembl gene	ENSG00000244617
Ensembl biotype	protein_coding
OMIM	611765
Entrez	151516

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000320256

RefSeq mRNA: 1 — MANE Select: NM_152792 NM_152792

CCDS: CCDS1897

Canonical transcript exons

ENST00000320256 — 1 exons

Exon	Start	End
ENSE00001221518	69960089	69961631

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 99.82.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4188 / max 359.6161, expressed in 35 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
28956	0.4188	35

Top tissues by expression

233 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
upper arm skin	UBERON:0004263	99.82	gold quality
upper leg skin	UBERON:0004262	99.56	gold quality
nipple	UBERON:0002030	98.64	gold quality
penis	UBERON:0000989	97.99	gold quality
skin of leg	UBERON:0001511	97.99	gold quality
skin of hip	UBERON:0001554	97.99	gold quality
mammalian vulva	UBERON:0000997	97.83	gold quality
zone of skin	UBERON:0000014	97.63	gold quality
skin of abdomen	UBERON:0001416	96.96	gold quality
pancreatic ductal cell	CL:0002079	88.09	silver quality
endothelial cell	CL:0000115	86.87	gold quality
blood	UBERON:0000178	81.48	gold quality
tibialis anterior	UBERON:0001385	80.26	silver quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.63	gold quality
amniotic fluid	UBERON:0000173	79.58	gold quality
ileal mucosa	UBERON:0000331	75.76	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	75.64	gold quality
spinal cord	UBERON:0002240	74.54	gold quality
hypothalamus	UBERON:0001898	72.37	gold quality
cerebellar hemisphere	UBERON:0002245	72.20	gold quality
right hemisphere of cerebellum	UBERON:0014890	72.08	gold quality
cerebellar cortex	UBERON:0002129	72.04	gold quality
deltoid	UBERON:0001476	72.02	silver quality
putamen	UBERON:0001874	72.00	gold quality
cerebellum	UBERON:0002037	71.68	gold quality
left ovary	UBERON:0002119	71.50	gold quality
substantia nigra	UBERON:0002038	71.23	gold quality
tibia	UBERON:0000979	71.04	gold quality
cortical plate	UBERON:0005343	70.89	gold quality
right frontal lobe	UBERON:0002810	70.87	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.85

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

37 targeting ASPRV1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-124-3P	99.89	73.74	3043
HSA-MIR-506-3P	99.89	73.55	3057
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-4739	99.84	65.25	1832
HSA-MIR-1321	99.84	65.30	1811
HSA-MIR-4756-5P	99.84	64.98	1809
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-1260A	99.61	66.67	1098
HSA-MIR-1260B	99.61	66.67	1098
HSA-MIR-486-3P	99.51	66.82	1901
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-330-3P	99.41	69.95	2521
HSA-MIR-183-3P	99.41	69.41	1598
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-6731-5P	99.28	67.42	2375
HSA-MIR-8085	99.28	67.56	2362
HSA-MIR-5582-5P	99.27	71.42	1879
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-4751	98.80	64.95	525
HSA-MIR-655-5P	98.74	65.93	888
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-4266	98.53	67.29	1035
HSA-MIR-1271-3P	97.56	64.85	865
HSA-MIR-550A-3-5P	97.56	65.35	823
HSA-MIR-550A-5P	97.56	65.35	823

Literature-anchored findings (GeneRIF, showing 7)

• Identification and characterization of a new member of the aspartic proteases family, a unique epidermal retroviral-like protease, Skin ASpartic Protease. (PMID:16098038)
• Taps expression is negatively associated with dedifferentiation and malignant progression in squamous cell carcinomas of the skin. (PMID:16565508)
• SASPase activity is indispensable for processing profilaggrin and maintaining the texture and hydration of the stratum corneum. (PMID:21542132)
• results failed to find an association between ASPRV1 gene mutations and atopic eczema or clinically dry skin in the European populations studied (PMID:22318384)
• Filaggrin and filaggrin 2 processing are linked together through skin aspartic acid protease activation. (PMID:32437351)
• Mutations in ASPRV1 Cause Dominantly Inherited Ichthyosis. (PMID:32516568)
• Biochemical Characterization of Human Retroviral-Like Aspartic Protease 1 (ASPRV1). (PMID:32640672)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Asprv1	ENSMUSG00000033508
rattus_norvegicus	Asprv1	ENSRNOG00000017710

Protein

Protein identifiers

Retroviral-like aspartic protease 1 — Q53RT3 (reviewed: Q53RT3)

Alternative names: Skin-specific retroviral-like aspartic protease, TPA-inducible aspartic proteinase-like protein

All UniProt accessions (1): Q53RT3

UniProt curated annotations — full annotation on UniProt →

Function. Protease responsible for filaggrin processing, essential for the maintenance of a proper epidermis organization.

Subunit / interactions. Homodimer.

Subcellular location. Membrane.

Tissue specificity. Expressed primarily in the granular layer of the epidermis and inner root sheath of hair follicles. In psoriatic skin, expressed throughout the stratum corneum. In ulcerated skin, expressed in the stratum granulosum of intact epidermis but almost absent from ulcerated regions. Expressed in differentiated areas of squamous cell carcinomas but not in undifferentiated tumors.

Post-translational modifications. Undergoes autocleavage which is necessary for activation of the protein.

Disease relevance. Ichthyosis, lamellar, autosomal dominant (ADLI) [MIM:146750] An autosomal dominant form of ichthyosis, a disorder of keratinization with abnormal differentiation and desquamation of the epidermis, resulting in abnormal skin scaling. ADLI is characterized by onset at birth or within the first months of life, skin scaling on the entire body with relative sparing of face, anterior chest, and abdomen, and palmoplantar keratoderma. Patients may manifest mild erythema and moderate pruritus. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53RT3-1	1	yes
Q53RT3-2	2

RefSeq proteins (1): NP_690005* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001969	Aspartic_peptidase_AS	Active_site
IPR001995	Peptidase_A2_cat	Domain
IPR021109	Peptidase_aspartic_dom_sf	Homologous_superfamily
IPR033539	Asprv1	Family

Pfam: PF13975

UniProt features (16 total): sequence variant 4, propeptide 2, topological domain 2, chain 1, mutagenesis site 1, sequence conflict 1, transmembrane region 1, domain 1, active site 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53RT3-F1	70.77	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 212

Glycosylation sites (1): 276

Mutagenesis-validated functional residues (1):

Position	Phenotype
212	abolishes production of active form of enzyme.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 115 (showing top): GOBP_PROTEIN_MATURATION, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, GOBP_SKIN_DEVELOPMENT, RICKMAN_HEAD_AND_NECK_CANCER_C, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, GOMF_ASPARTIC_TYPE_PEPTIDASE_ACTIVITY, chr2p13, MIKKELSEN_ES_ICP_WITH_H3K4ME3, CHYLA_CBFA2T3_TARGETS_DN, BRUINS_UVC_RESPONSE_VIA_TP53_GROUP_A, GOBP_PROTEIN_PROCESSING, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, GSE13522_CTRL_VS_T_CRUZI_BRAZIL_STRAIN_INF_SKIN_DN, GSE11924_TH2_VS_TH17_CD4_TCELL_UP

GO Biological Process (3): protein processing (GO:0016485), skin development (GO:0043588), proteolysis (GO:0006508)

GO Molecular Function (3): aspartic-type endopeptidase activity (GO:0004190), peptidase activity (GO:0008233), hydrolase activity (GO:0016787)

GO Cellular Component (1): membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
proteolysis	1
protein maturation	1
animal organ development	1
protein metabolic process	1
endopeptidase activity	1
aspartic-type peptidase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
catalytic activity	1
cellular anatomical structure	1

Protein interactions and networks

STRING

400 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ASPRV1	BLMH	Q13867	521
ASPRV1	CASP14	P31944	518
ASPRV1	PNPLA1	Q8N8W4	480
ASPRV1	MRC1	P22897	477
ASPRV1	NIPAL4	Q0D2K0	474
ASPRV1	FLG2	Q5D862	401
ASPRV1	TGM1	P22735	387
ASPRV1	NUBP2	Q9Y5Y2	377
ASPRV1	PRSS8	Q16651	359
ASPRV1	KRT27	Q7Z3Y8	354
ASPRV1	CERS3	Q8IU89	353
ASPRV1	H8Y6P7	H8Y6P7	348
ASPRV1	ABCA12	Q86UK0	342
ASPRV1	CYSRT1	A8MQ03	324
ASPRV1	LIPN	Q5VXI9	322

IntAct

23 interactions, top by confidence:

A	B	Type	Score
MCL1	PRKAB2	psi-mi:“MI:0914”(association)	0.640
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
RAB9B	CHM	psi-mi:“MI:0914”(association)	0.530
ASPRV1	WDR45B	psi-mi:“MI:0914”(association)	0.530
ELMOD3	ASPRV1	psi-mi:“MI:0915”(physical association)	0.400
	GNAT3	psi-mi:“MI:0915”(physical association)	0.400
ASPRV1	SLC25A6	psi-mi:“MI:0915”(physical association)	0.400
CDKN2A	ASPRV1	psi-mi:“MI:0915”(physical association)	0.370
CUL2	ANXA2P2	psi-mi:“MI:0914”(association)	0.350
FCF1	SULT2B1	psi-mi:“MI:0914”(association)	0.350
SLX4	MYO1C	psi-mi:“MI:0914”(association)	0.350
TIFAB	DDX3X	psi-mi:“MI:0914”(association)	0.350
ST6GALNAC6	A2ML1	psi-mi:“MI:0914”(association)	0.350
PPP2R2B	A2ML1	psi-mi:“MI:0914”(association)	0.350
CCR1	UBA6	psi-mi:“MI:0914”(association)	0.350
PIGT	A2ML1	psi-mi:“MI:0914”(association)	0.350
FNDC5	A2ML1	psi-mi:“MI:0914”(association)	0.350
ZC3HC1	SULT2B1	psi-mi:“MI:0914”(association)	0.350
SMPD2	A2ML1	psi-mi:“MI:0914”(association)	0.350
MYB	A2ML1	psi-mi:“MI:0914”(association)	0.350

BioGRID (35): ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), WDR45B (Affinity Capture-MS), GNB1L (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Affinity Capture-MS), ASPRV1 (Two-hybrid)

ESM2 similar proteins: A4FUB7, A6NKG5, O60290, O89290, O91080, P03975, P04023, P04584, P05896, P05897, P0C691, P0CG32, P11365, P12451, P12502, P15833, P17192, P17757, P18096, P19505, P20876, P24107, P24740, P30028, P35125, Q09PK2, Q1A267, Q4R6I1, Q52QI2, Q53RT3, Q5DTT4, Q5HYW3, Q5HZA3, Q66403, Q66H30, Q6PEW1, Q74120, Q76634, Q77373, Q7M732

Diamond homologs: Q09PK2, Q53RT3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

87 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	65
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
977277	NM_152792.4(ASPRV1):c.343A>G (p.Lys115Glu)	Pathogenic
977278	NM_152792.4(ASPRV1):c.688C>A (p.Pro230Thr)	Pathogenic
977279	NM_152792.4(ASPRV1):c.680G>C (p.Arg227Pro)	Pathogenic

SpliceAI

121 predictions. Top by Δscore:

Variant	Effect	Δscore
2:69961477:A:T	acceptor_gain	0.9700
2:69961471:C:T	acceptor_gain	0.9600
2:69961476:C:CT	acceptor_gain	0.9500
2:69960655:T:TA	donor_gain	0.9400
2:69961471:C:CT	acceptor_gain	0.9100
2:69961473:C:CT	acceptor_gain	0.9000
2:69960670:T:TA	donor_gain	0.8100
2:69960667:AGCT:A	donor_gain	0.7900
2:69961476:C:T	acceptor_gain	0.7500
2:69960659:A:AC	donor_gain	0.7400
2:69960700:T:TA	donor_gain	0.7200
2:69961532:C:G	acceptor_gain	0.7000
2:69960618:TCCC:T	donor_gain	0.6800
2:69961459:TCA:T	acceptor_gain	0.6500
2:69960668:G:C	donor_gain	0.6400
2:69960619:C:A	donor_gain	0.6300
2:69961564:TTGG:T	acceptor_gain	0.5800
2:69960624:CAATA:C	donor_gain	0.5600
2:69960768:C:A	donor_gain	0.5600
2:69960620:C:T	donor_gain	0.5400
2:69960660:G:C	donor_gain	0.5300
2:69961604:C:CC	acceptor_gain	0.5200
2:69961533:T:TG	acceptor_gain	0.4900
2:69960509:CCC:C	acceptor_gain	0.4500
2:69960510:CCC:C	acceptor_gain	0.4500
2:69961603:A:AC	acceptor_gain	0.4400
2:69960617:TTCC:T	donor_gain	0.4300
2:69961286:G:C	donor_gain	0.4300
2:69961460:C:A	acceptor_gain	0.4300
2:69960727:T:C	donor_gain	0.4100

AlphaMissense

2241 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:69960874:A:G	F272S	0.999
2:69960760:A:G	F310S	0.998
2:69960780:G:C	C303W	0.998
2:69960782:A:G	C303R	0.998
2:69960873:G:C	F272L	0.998
2:69960873:G:T	F272L	0.998
2:69960875:A:G	F272L	0.998
2:69960920:A:G	W257R	0.998
2:69960920:A:T	W257R	0.998
2:69961014:C:A	W225C	0.998
2:69961014:C:G	W225C	0.998
2:69961016:A:G	W225R	0.998
2:69961016:A:T	W225R	0.998
2:69961030:A:T	V220D	0.998
2:69961053:G:C	D212E	0.998
2:69961053:G:T	D212E	0.998
2:69961054:T:A	D212V	0.998
2:69961054:T:C	D212G	0.998
2:69961054:T:G	D212A	0.998
2:69961063:A:G	F209S	0.998
2:69960823:A:G	L289P	0.997
2:69960823:A:T	L289H	0.997
2:69960925:C:A	G255V	0.997
2:69961015:C:G	W225S	0.997
2:69961096:A:G	L198P	0.997
2:69960754:A:G	L312P	0.996
2:69960808:G:T	A294D	0.996
2:69960838:A:T	I284N	0.996
2:69961036:G:A	S218F	0.996
2:69961055:C:G	D212H	0.996

dbSNP variants (sampled 300 via entrez): RS1000001957 (2:69947341 A>C), RS1000054458 (2:69985078 G>A,C), RS1000084494 (2:70022709 A>G,T), RS1000105085 (2:69953126 G>A), RS1000113710 (2:69991513 C>T), RS1000138046 (2:70059189 C>A), RS1000145647 (2:70008979 C>T), RS1000167059 (2:70006551 G>A,C), RS1000169427 (2:70043979 T>C), RS1000184399 (2:69976501 A>G), RS1000196811 (2:69961885 A>G), RS1000225671 (2:70086135 C>A), RS1000235869 (2:70080419 G>A), RS1000255782 (2:70051238 AT>A), RS1000280949 (2:70035208 G>A)

Disease associations

OMIM: gene MIM:611765 | disease phenotypes: MIM:146750

GenCC curated gene-disease

Disease	Classification	Inheritance
ichthyosis, lamellar, autosomal dominant	Strong	Autosomal dominant

Mondo (2): prostate cancer (MONDO:0008315), ichthyosis, lamellar, autosomal dominant (MONDO:0007812)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

23 total (23 of 23 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000083	Renal insufficiency
HP:0000164	Abnormality of the dentition
HP:0000232	Everted lower lip vermilion
HP:0000389	Chronic otitis media
HP:0000656	Ectropion
HP:0000958	Dry skin
HP:0000962	Hyperkeratosis
HP:0000989	Pruritus
HP:0001019	Erythroderma
HP:0001597	Abnormal nail morphology
HP:0001944	Dehydration
HP:0002205	Recurrent respiratory infections
HP:0004322	Short stature
HP:0007479	Congenital nonbullous ichthyosiform erythroderma
HP:0008064	Ichthyosis
HP:0008070	Sparse hair
HP:0011039	Abnormal helix morphology
HP:0100543	Cognitive impairment
HP:0100679	Lack of skin elasticity
HP:0100758	Gangrene
HP:0100806	Sepsis
HP:0100840	Aplasia/Hypoplasia of the eyebrow

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002481_1	Acne (severe)	5.000000e-06

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C537263	Lamellar ichthyosis, autosomal dominant form (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

29 total (human), top 29 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases expression, decreases methylation, affects cotreatment, increases expression	3
Benzo(a)pyrene	decreases expression, increases methylation, increases mutagenesis	3
Diethylhexyl Phthalate	decreases expression, decreases methylation, increases abundance	2
Cadmium Chloride	increases abundance, increases expression, decreases expression	2
aristolochic acid I	increases expression	1
bisphenol F	affects cotreatment, increases expression	1
lasiocarpine	decreases expression	1
triphenyl phosphate	affects expression	1
sodium arsenate	decreases expression, increases abundance	1
tris(2-butoxyethyl) phosphate	affects expression	1
mono-(2-ethylhexyl)phthalate	decreases methylation, increases abundance	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
hydroquinone	increases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
abrine	increases expression	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	increases expression	1
Arsenic	increases abundance, decreases expression	1
Cadmium	decreases expression, increases abundance	1
Dexamethasone	increases expression, affects cotreatment	1
Indomethacin	affects cotreatment, increases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
Quercetin	increases expression	1
Tobacco Smoke Pollution	decreases expression	1
Valproic Acid	increases methylation	1
1-Methyl-3-isobutylxanthine	affects cotreatment, increases expression	1
Aflatoxin B1	decreases expression	1
Copper Sulfate	decreases expression	1
Lactic Acid	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer